These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 11896447)

  • 1. Effectiveness of insulin-like growth factor I receptor antisense strategy against Ewing's sarcoma cells.
    Scotlandi K; Maini C; Manara MC; Benini S; Serra M; Cerisano V; Strammiello R; Baldini N; Lollini PL; Nanni P; Nicoletti G; Picci P
    Cancer Gene Ther; 2002 Mar; 9(3):296-307. PubMed ID: 11896447
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of an IGF-I receptor dominant negative mutant induces apoptosis, inhibits tumorigenesis and enhances chemosensitivity in Ewing's sarcoma cells.
    Scotlandi K; Avnet S; Benini S; Manara MC; Serra M; Cerisano V; Perdichizzi S; Lollini PL; De Giovanni C; Landuzzi L; Picci P
    Int J Cancer; 2002 Sep; 101(1):11-6. PubMed ID: 12209582
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Down-regulation of the insulin-like growth factor I receptor by antisense RNA can reverse the transformed phenotype of human cervical cancer cell lines.
    Nakamura K; Hongo A; Kodama J; Miyagi Y; Yoshinouchi M; Kudo T
    Cancer Res; 2000 Feb; 60(3):760-5. PubMed ID: 10676665
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Contribution of MEK/MAPK and PI3-K signaling pathway to the malignant behavior of Ewing's sarcoma cells: therapeutic prospects.
    Benini S; Manara MC; Cerisano V; Perdichizzi S; Strammiello R; Serra M; Picci P; Scotlandi K
    Int J Cancer; 2004 Jan; 108(3):358-66. PubMed ID: 14648701
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of insulin-like growth factor I receptor increases the antitumor activity of doxorubicin and vincristine against Ewing's sarcoma cells.
    Benini S; Manara MC; Baldini N; Cerisano V; Massimo Serra ; Mercuri M; Lollini PL; Nanni P; Picci P; Scotlandi K
    Clin Cancer Res; 2001 Jun; 7(6):1790-7. PubMed ID: 11410521
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of human breast cancer cells with antisense RNA to the type I insulin-like growth factor receptor inhibits cell growth, suppresses tumorigenesis, alters the metastatic potential, and prolongs survival in vivo.
    Chernicky CL; Yi L; Tan H; Gan SU; Ilan J
    Cancer Gene Ther; 2000 Mar; 7(3):384-95. PubMed ID: 10766344
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of IGF-I/IGF-IR circuit on the angiogenetic properties of Ewing's sarcoma cells.
    Strammiello R; Benini S; Manara MC; Perdichizzi S; Serra M; Spisni E; Picci P; Scotlandi K
    Horm Metab Res; 2003; 35(11-12):675-84. PubMed ID: 14710346
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phosphoinositide 3-hydroxide kinase blockade enhances apoptosis in the Ewing's sarcoma family of tumors.
    Toretsky JA; Thakar M; Eskenazi AE; Frantz CN
    Cancer Res; 1999 Nov; 59(22):5745-50. PubMed ID: 10582694
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of murine breast cancer cells with antisense RNA to the type I insulin-like growth factor receptor decreases the level of plasminogen activator transcripts, inhibits cell growth in vitro, and reduces tumorigenesis in vivo.
    Chernicky CL; Tan H; Yi L; Loret de Mola JR; Ilan J
    Mol Pathol; 2002 Apr; 55(2):102-9. PubMed ID: 11950959
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antisense RNA to the type I insulin-like growth factor receptor suppresses tumor growth and prevents invasion by rat prostate cancer cells in vivo.
    Burfeind P; Chernicky CL; Rininsland F; Ilan J; Ilan J
    Proc Natl Acad Sci U S A; 1996 Jul; 93(14):7263-8. PubMed ID: 8692980
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of proliferation in human MNNG/HOS osteosarcoma and SK-ES-1 Ewing sarcoma cell lines in vitro and in vivo by antagonists of growth hormone-releasing hormone: effects on insulin-like growth factor II.
    Braczkowski R; Schally AV; Plonowski A; Varga JL; Groot K; Krupa M; Armatis P
    Cancer; 2002 Oct; 95(8):1735-45. PubMed ID: 12365022
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Blockade of the type I IGF receptor expression in human prostate cancer cells inhibits proliferation and invasion, up-regulates IGF binding protein-3, and suppresses MMP-2 expression.
    Grzmil M; Hemmerlein B; Thelen P; Schweyer S; Burfeind P
    J Pathol; 2004 Jan; 202(1):50-9. PubMed ID: 14694521
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted therapies in Ewing's sarcoma.
    Scotlandi K
    Adv Exp Med Biol; 2006; 587():13-22. PubMed ID: 17163152
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical evidence that use of TRAIL in Ewing's sarcoma and osteosarcoma therapy inhibits tumor growth, prevents osteolysis, and increases animal survival.
    Picarda G; Lamoureux F; Geffroy L; Delepine P; Montier T; Laud K; Tirode F; Delattre O; Heymann D; Rédini F
    Clin Cancer Res; 2010 Apr; 16(8):2363-74. PubMed ID: 20371692
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The molecular mechanisms responsible for resistance to ET-743 (Trabectidin; Yondelis) in the Ewing's sarcoma cell line, TC-71.
    Manara MC; Perdichizzi S; Serra M; Pierini R; Benini S; Hattinger CM; Astolfi A; Bagnati R; D'Incalci M; Picci P; Scotlandi K
    Int J Oncol; 2005 Dec; 27(6):1605-16. PubMed ID: 16273217
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effective molecular targeting of CDK4/6 and IGF-1R in a rare FUS-ERG fusion CDKN2A-deletion doxorubicin-resistant Ewing's sarcoma patient-derived orthotopic xenograft (PDOX) nude-mouse model.
    Murakami T; Singh AS; Kiyuna T; Dry SM; Li Y; James AW; Igarashi K; Kawaguchi K; DeLong JC; Zhang Y; Hiroshima Y; Russell T; Eckardt MA; Yanagawa J; Federman N; Matsuyama R; Chishima T; Tanaka K; Bouvet M; Endo I; Eilber FC; Hoffman RM
    Oncotarget; 2016 Jul; 7(30):47556-47564. PubMed ID: 27286459
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical in vivo study of new insulin-like growth factor-I receptor--specific inhibitor in Ewing's sarcoma.
    Manara MC; Landuzzi L; Nanni P; Nicoletti G; Zambelli D; Lollini PL; Nanni C; Hofmann F; García-Echeverría C; Picci P; Scotlandi K
    Clin Cancer Res; 2007 Feb; 13(4):1322-30. PubMed ID: 17317844
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Growth inhibition of MCF-7 breast cancer cells by stable expression of an insulin-like growth factor I receptor antisense ribonucleic acid.
    Neuenschwander S; Roberts CT; LeRoith D
    Endocrinology; 1995 Oct; 136(10):4298-303. PubMed ID: 7664648
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [shRNA-mediated insulin-like growth factor I receptor gene silencing inhibits cell proliferation, induces cell apoptosis, and suppresses tumor growth in non-small cell lung cancer: in vitro and in vivo experiments].
    Dong AQ; Kong MJ; Ma ZY; Qian JF; Fan JQ; Xu XH
    Zhonghua Yi Xue Za Zhi; 2007 Jun; 87(21):1506-9. PubMed ID: 17785094
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of insulin-like growth factors-IR and -IIR antisense gene transfection on the biological behaviors of SMMC-7721 human hepatoma cells.
    Yang JM; Chen WS; Liu ZP; Luo YH; Liu WW
    J Gastroenterol Hepatol; 2003 Mar; 18(3):296-301. PubMed ID: 12603530
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.